证券日报网讯12月22日，津药药业（600488）在互动平台回答投资者提问时表示，截至2025年12月10 日，公司股东数为38026户。 ...

Core Viewpoint - Tianjin Pharmaceutical Industry is undergoing a strategic transformation from a "production-driven" model to a "dual empowerment of R&D and market" approach, as indicated by the company's recent organizational changes and focus on core business areas [2][3]. Group 1: Organizational Changes - In September 2023, Tianjin Pharmaceutical established two main centers for raw material manufacturing and sales, with additional centers for product planning and R&D set to launch in early 2024 [2]. - The company aims to optimize its organizational structure to adapt to new industry dynamics, reflecting a comprehensive strategic choice beyond merely rebranding [2]. Group 2: Focus on Core Areas - The company is concentrating on critical therapeutic areas such as emergency medicine, dermatology, ophthalmology, anesthetics, respiratory, and autoimmune diseases, based on thorough research into disease patterns and clinical needs [3]. - The raw material manufacturing center achieved a capacity utilization rate of 92% this month, showcasing operational efficiency [3]. Group 3: R&D Investment and Innovation - Over the past three years, the company has invested more than 150 million yuan annually in R&D, with the R&D expense ratio expected to rise to 7.7% in 2024 [4]. - The company has developed several products in dermatology and ophthalmology, including the domestically exclusive Difluprednate eye drops set to launch in 2025, utilizing new technology for better drug penetration [4][5]. Group 4: Internationalization Strategy - The company is pursuing an "integrated development of domestic and international sales" strategy, leveraging its advantages in raw material and formulation integration to achieve resource sharing and market synergy [5][6]. - Tianjin Pharmaceutical is transitioning from "product export" to "capability export," aiming to build a global supply chain and local production capacity in countries along the Belt and Road Initiative [6]. Group 5: Compliance and Long-term Stability - Compliance is emphasized as a fundamental principle for sustainable growth, with the company implementing a comprehensive compliance management system and ensuring that all key personnel sign compliance commitments [7]. - The company maintains a competitive edge in the steroid hormone sector, with over 80% self-sufficiency in key raw materials and numerous international certifications [7][8]. Group 6: Long-term Vision - The company views the pharmaceutical industry as a marathon rather than a sprint, focusing on deep specialization in steroids and long-term innovation to solidify its development foundation [8][9].

Core Viewpoint - The company's performance is influenced by multiple external factors including drug procurement policies, terminal medication demand, and international market competition [1] Group 1 - The company is committed to closely monitoring market dynamics [1] - The company plans to flexibly adjust sales strategies [1] - The company aims to deepen market precision operations [1] Group 2 - The company is accelerating the research and development of new potential products [1] - The company seeks to enhance its overall competitive capabilities [1] - The company intends to maintain stable operations [1]

Core Viewpoint - The market regulatory authority is maintaining a high-pressure approach to combat monopolistic practices in the pharmaceutical sector, resulting in significant price reductions for drugs, which have decreased by over 40%, with some prices dropping by as much as 95% [1][3]. Group 1: Regulatory Actions - The State Administration for Market Regulation (SAMR) has prioritized the crackdown on monopolistic behaviors in the pharmaceutical industry, having investigated 12 cases of monopolistic agreements and abuse of market dominance over the past three years, with total fines exceeding 2.4 billion yuan [1][2]. - Key cases include fines of 1.219 billion yuan for Shanghai Pharmaceutical Biochemical, 362 million yuan for Tianjin Pharmaceutical Industry (600488), and 223 million yuan for Shanghai Xinyi United, which serve as a strong deterrent against illegal practices [1][2]. Group 2: Enforcement Strategies - The enforcement strategy includes a "quick investigation and handling" approach, focusing on critical drugs such as those in short supply or essential for emergency treatment, with over 850 personnel deployed to investigate more than 40 upstream and downstream companies across 10 provinces [1][2]. - The SAMR has adopted a "severe penalties" policy, with an average fine of over 200 million yuan per case, equating to 5% of the previous year's sales for the companies involved, and in some cases, penalties reaching 10% of sales [2]. - The agency emphasizes "case-driven governance," having established guidelines for identifying monopolistic behaviors in the pharmaceutical sector, thereby enhancing compliance and governance [2]. Group 3: Impact on Drug Prices - The enforcement actions have led to significant price reductions for specific drugs, such as a 95.8% decrease for polymyxin B sulfate injection and a 58.6% decrease for methacholine chloride injection, benefiting consumers and reducing national healthcare expenditures [3]. - The SAMR plans to continue focusing on the pharmaceutical sector for antitrust enforcement, aiming to maintain fair competition and protect consumer interests [3].

Group 1: Antitrust Enforcement Achievements - The State Administration for Market Regulation (SAMR) has focused on addressing monopolistic issues that are of significant concern to the public, resulting in the investigation of 35 monopoly agreement cases and 25 abuse of market dominance cases over the past three years, with a total fine of 2.93 billion yuan [1] - SAMR has concluded 950 cases related to business concentration in the consumer sector, supporting companies in enhancing operational efficiency through mergers and acquisitions [1] - The agency has also resolved 148 cases involving the abuse of administrative power to eliminate or restrict competition, addressing issues such as local protectionism and market segmentation [1] Group 2: Pharmaceutical Sector Focus - SAMR has maintained a stringent enforcement stance in the pharmaceutical sector, investigating 12 major cases over three years, with significant fines imposed on companies such as Shanghai Pharmaceuticals and Tianjin Pharmaceutical, totaling 1.219 billion yuan, 362 million yuan, and 223 million yuan respectively [2] - The enforcement actions have led to price reductions of over 40% for involved drugs, with some prices dropping by as much as 95%, thereby reducing patient medication costs and national healthcare expenditures [2] - SAMR aims to continue prioritizing antitrust enforcement in the pharmaceutical sector, focusing on severe and rapid investigations of major monopolistic cases to maintain fair competition and protect consumer interests [2] Group 3: Platform Economy Regulation - The rapid development of the platform economy in China has introduced unique competitive characteristics, such as significant scale and network effects, leading to a tendency for leading platform companies to engage in cross-industry competition and rapid expansion [3] - The SAMR has identified prominent antitrust risks in the platform economy, noting that platform companies need to enhance their awareness and capability regarding antitrust compliance [3] - To address these challenges, SAMR has developed the "Antitrust Compliance Guidelines for Internet Platforms," aimed at guiding platform companies in risk identification, management, and compliance to effectively mitigate antitrust risks and promote healthy development of the platform economy [3]

Core Viewpoint - The board of directors of Tianyao Pharmaceutical Co., Ltd. held its 22nd meeting of the 9th session on November 28, 2025, to approve the performance assessment results and salary determination for senior management for the year 2024 [1][4]. Group 1 - The meeting was conducted via telecommunication and was attended by all 9 directors, meeting the requirements of the Company Law and the company's articles of association [1]. - The performance assessment results for senior management in 2024 were reviewed and approved, with related directors abstaining from the vote [1]. - The voting results showed 6 votes in favor, 0 against, and 0 abstentions [2].

Group 1 - The core point of the article is that Tianyao Pharmaceutical (SH 600488) announced the results of its board meeting held on November 28, 2025, which included discussions on the performance evaluation and compensation of senior management for the year 2024 [1] - For the first half of 2025, Tianyao Pharmaceutical's revenue composition was as follows: steroid hormones accounted for 62.47%, formulations for 27.95%, amino acid raw materials for 8.98%, and other businesses for 0.57% [1] - As of the report date, Tianyao Pharmaceutical's market capitalization was 4.7 billion yuan [1]

证券代码：600488 证券简称：津药药业 编号：2025-069 津药药业股份有限公司 第九届董事会第二十二次会议决议公告 津药药业股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 2025 年 11 月 28 日 津药药业股份有限公司（以下简称"公司"）第九届董事会第二 十二次会议于 2025 年 11 月 28 日以通讯表决的方式召开。本次会议 的通知已于 2025 年 11 月 24 日以电子邮件的方式送达公司各位董事 和高管人员。会议应出席董事 9 人，实际出席董事 9 人。会议符合《中 华人民共和国公司法》（以下简称"《公司法》"）和《津药药业股份有 限公司章程》（以下简称"《公司章程》"）的有关规定，决议如下： 1 表决结果：同意票 6 票，反对票 0 票，弃权票 0 票。 特此公告。 审议通过关于公司高级管理人员 2024 年度绩效考核结果与薪酬 核定的议案 公司对高级管理人员 2024 年度经营业绩考核指标完成情况进行 核定，形成高级管理人员 2024 年度绩效考核与薪酬核定结果。关联 ...

11月28日，津药药业盘中下跌2.05%，截至13:19，报4.29元/股，成交2124.42万元，换手率0.45%，总市 值46.84亿元。 资金流向方面，主力资金净流出96.80万元，特大单买入0.00元，占比0.00%，卖出161.09万元，占比 7.58%；大单买入173.93万元，占比8.19%，卖出109.63万元，占比5.16%。 津药药业今年以来股价涨3.57%，近5个交易日涨1.66%，近20日涨1.42%，近60日涨0.00%。 津药药业所属申万行业为：医药生物-化学制药-原料药。所属概念板块包括：低价、小盘、肝炎治疗、 原料药、辅助生殖等。 截至11月20日，津药药业股东户数3.82万，较上期减少1.87%；人均流通股28566股，较上期增加 1.90%。2025年1月-9月，津药药业实现营业收入22.32亿元，同比减少13.24%；归母净利润6953.99万 元，同比减少62.75%。 分红方面，津药药业A股上市后累计派现6.88亿元。近三年，累计派现2.13亿元。 机构持仓方面，截止2025年9月30日，津药药业十大流通股东中，香港中央结算有限公司位居第三大流 通股东，持股1486. ...

Group 1 - The company Tianjin Pharmaceutical Industry announced on November 24 that as of November 20, 2025, the number of its shareholders will be 38,222 [2]